(Co. Reg. No: 200405621W)

NEWS RELEASE

Breakthrough Sublingual Wafers Raise NAD+ Levels by 76% and Enhance Well-Being in Human Trial

- ✓ SL-NAD+ wafers demonstrated in human trial to:
  - ➢ significantly increase blood NAD+ levels by 59% over two weeks and 76% over six weeks compared to baseline
  - ➢ improve energy levels, mood, sleep quality, mental clarity, and physical strength
  - ➢ be safe and well tolerated

Singapore, 9 July 2024 — iX Biopharma Ltd (the "**Company**"), a specialty pharmaceutical company specializing in drug delivery systems and a leader in innovative healthspan nutraceuticals, announced today the top-line results from an open-label, pilot study conducted in London, United Kingdom by NAD Laboratory Ltd, evaluating the effects of its novel sublingual NAD+ (nicotinamide adenine dinucleotide) wafer (SL-NAD+) on NAD+ levels in nine healthy individuals.

The study showed a significant increase in blood NAD+ levels, with an average rise of 59% at two weeks and 76% at six weeks compared to baseline.

In addition to boosting NAD+ levels, the study showed that SL-NAD+ wafers also improved various aspects of health and wellness in the participants. According to a self-reported questionnaire, participants reported enhancements in energy levels, mood, sleep quality, mental clarity, and/or physical strength, which were sustained throughout the six-week study period. Moreover, SL-NAD+ wafers were safe and well tolerated.

These results add to a growing body of evidence that the supplementation of NAD is a good way to improve the quality of life as one ages. However, SL-NAD+ is the only scientifically proven consumer product that delivers pure NAD+ via the oral mucosa to effectively increase NAD+ levels, making it the most direct and efficient way to boost NAD+ levels and enjoy its benefits. Its advantages include:

- ✓ effective sublingual delivery for better bioavailability and quicker uptake;
- ✓ consistent dosing with no need for conversion to NAD+ compared to NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) precursor supplements; and
- ✓ in comparison to NAD+ IV drips, it is more practical, convenient, affordable, and readily available, providing a way for continuous supplementation to maintain constant, optimal NAD+ levels.

"We are very pleased with the outcome of this study, which now confirms that SL-NAD+ wafers can significantly raise NAD+ levels when measured in plasma and within red blood cells," said **Dr Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer** of the Company. *"This achievement is made possible by the Company's proprietary freeze-drying process, which stabilises NAD+, and our patented wafer formulation, ensuring rapid disintegration, release, and increased absorption, unlocking the full benefits of this critical molecule. This is a breakthrough for the field of longevity science and for millions of people who want to optimise their cellular health."*

About NAD+ and SL-NAD+

NAD (nicotinamide adenine dinucleotide) is a critical molecule in our body responsible for vital cellular functions in the body. It is crucial for energy production, cellular metabolism, DNA repair, regulating sleep cycles and promoting healthy aging. NAD+ levels decrease as we age, with levels typically dropping to half by the time we reach 50. The decline in NAD+ levels with age is linked to various age-related health concerns and metabolic disorders. In recent years, NAD+ has become an important focus in scientific research on aging, with maintenance of adequate NAD+ levels being linked to healthy aging and longevity. Clinical trials have also been conducted to investigate the potential of NAD+ in treating various age-related diseases, such as Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease, neurodegenerative diseases like Parkinson's disease, cardiovascular and skeletal muscle diseases.

Despite its potential, NAD+ has been challenging to utilise effectively, other than through IV. Alternative ways to boost NAD+ levels with NAD precursors, like NMN and NR, may be inefficient due to bioavailability and other issues, such as inefficient conversion to NAD+ due to age-related declines in enzyme activity.

SL-NAD+ is a novel sublingual wafer that delivers NAD+ directly into the bloodstream, bypassing the digestive system to ensure higher bioavailability and significantly boosting intracellular NAD+ levels. The Company's proprietary freeze-drying process and patented wafer formulation stabilises NAD+ and delivers them as nanoparticles, ensuring rapid disintegration, release, and absorption through the sublingual mucosa. SL-NAD+ is available for purchase on https://entity-health.com/product/sl-nad/ and through select specialist clinics in Singapore.

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of pharmaceutical drugs and innovative nutraceuticals using novel, patent-protected formulations for sublingual delivery.

iX Biopharma has developed a number of patented drug delivery platform technologies, including WaferiX, WaferlogiX and NADiX, which deliver small molecule and biologics sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The drug delivery platforms are particularly useful for drug repurposing, where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk. iX Biopharma's portfolio includes among others, ketamine, dexmedetomidine, sublingual vaccine delivery, and healthspan products.

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com